Expanded Access Use of INCB054329 to Treat a Single Patient With Metastatic Renal Cell Carcinoma
NCT ID: NCT03896815
Last Updated: 2019-04-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NO_LONGER_AVAILABLE
EXPANDED_ACCESS
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors
NCT02903914
IB-T101 Injection for Treatment of Patients with Advanced Clear Cell Renal Cell Carcinoma
NCT06819293
Ispinesib in Treating Patients With Metastatic or Unresectable Kidney Cancer
NCT00354250
A Safety, Tolerability and Efficacy Study of E7070 in Patients With Renal Cell Carcinoma
NCT00059735
Interferon Alfa in Treating Patients With Advanced Kidney Cancer
NCT00003542
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
INCB054329
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Incyte Corporation
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bryan Schneider, MD
Role: PRINCIPAL_INVESTIGATOR
University of Michigan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
I-54329-17-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.